Entero Healthcare Solutions has informed stock exchanges about a temporary suspension of its subsidiary's drug manufacturing license, marking a regulatory setback for the pharmaceutical company. The disclosure was made on January 27, 2026, in compliance with SEBI listing regulations.

Regulatory Action Details

The Senior Drugs Control Officer cum Licensing Authority, Karnal Zone, has temporarily suspended the drug license of Atreja Healthcare Solutions Private Limited, a wholly owned subsidiary of Entero Healthcare Solutions. The suspension is effective for three days, from January 30, 2026, to February 1, 2026.

Violation Specifics

The temporary suspension was imposed as an administrative action for contraventions of provisions under the Drugs and Cosmetics Act, 1940, read with rule 64 and 65 (5) of the Drugs and Cosmetics Rules, 1945. The regulatory action was taken while Atreja was conducting its business operations.

Financial Impact Assessment

The company has provided a detailed assessment of the suspension's impact on its operations and financial performance:

Regulatory Compliance

Entero Healthcare Solutions filed this disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required under SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The disclosure was signed by Sanu Kapoor, Vice President-General Counsel, Company Secretary & Compliance Officer, ensuring proper corporate governance protocols were followed in communicating this development to stakeholders and regulatory authorities.

Entero Healthcare Solutions has notified stock exchanges regarding a structural change in its statutory auditor. The company's auditing firm M S K A & Associates has converted itself into a Limited Liability Partnership (LLP) and is now operating as M S K A & Associates LLP, Chartered Accountants.

Conversion Details

The conversion took effect on January 13, 2026, under the provisions of the Limited Liability Partnership Act, 2008. The auditing firm communicated this change to Entero Healthcare Solutions through a letter dated January 14, 2026.

Audit Engagement Continuity

Entero Healthcare Solutions has confirmed that the conversion does not impact the existing audit arrangement. M S K A & Associates LLP will continue to discharge their obligations as statutory auditors for the remaining tenure of their appointment. The audit engagement remains unchanged despite the structural transformation of the auditing firm.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Sanu Kapoor signed the intimation letter to both BSE and NSE on January 15, 2026.

The notification was sent to the Head of Listing Compliance Department at both stock exchanges, ensuring proper regulatory compliance and maintaining transparency with stakeholders regarding this administrative change in the company's statutory auditor structure.